{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:49:36Z","timestamp":1791355776042,"version":"4.3.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Central serous chorioretinopathy (CSCR) is characterized by retinal pigment epithelium dysfunction and choroidal hyperpermeability. Beyond established associations such as psychosocial stress and corticosteroid exposure, experimental and epidemiological findings raise the possibility that mast cell and histamine-related pathways may contribute to CSCR pathophysiology. This study reviews mechanistic and clinical evidence for the role of histamine in the pathogenesis of CSCR, as well as the role of histamine-targeted therapies in this condition. We also present two cases, highlighting the possible therapeutic role of anti-allergy agents in CSCR.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched Ovid MEDLINE, Embase, and Cochrane CENTRAL to October 2025 for studies of antihistamines and\/or mast-cell stabilizers, alone or in combination in central serous retinopathy and pachychoroid spectrum diseases. Eligible designs included human observational and controlled studies. Two reviewers independently screened, extracted, and appraised data using ROBINS-I, NOS, and GRADE. Results were narratively synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After screening 316 articles, three studies (430 patients, 390 controls) from India and the United States were included. Direct evidence for anti-allergy therapeutics was limited to a single management series, in which short-course antihistamine treatment showed no meaningful visual or anatomical benefit; however, improvements occurred spontaneously or after focal laser. One case\u2013control study reported a higher prevalence of antihistamine use and allergic disorders among CSCR patients (OR 4.1), suggesting a possible histamine-mediated risk. Another case-control study found no statistically significant association between antihistamine use and CSCR after multivariable adjustment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Analysis of the literature revealed inconsistent associations between antihistamine use and CSCR risk, with a brief therapeutic trial offering no benefit for acute CSCR. However, two illustrative cases demonstrate temporal associations between interruption of anti-allergic therapy and subsequent CSCR activity, followed by anatomical improvement after treatment re-initiation or modification. These observations are hypothesis-generating but cannot establish therapeutic efficacy or causality, particularly given concurrent treatment changes in case 1. Given the inconclusive therapeutic data, further randomized controlled trials are warranted to more rigorously evaluate sustained mast-cell stabilization regimens before drawing clinical conclusions.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1799560","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:51:01Z","timestamp":1791352261000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Histamine-mediated inflammation and mast cell modulation in central serous chorioretinopathy: a two case illustrations"],"prefix":"10.3389","volume":"17","author":[{"given":"Sara","family":"KamaliZonouzi","sequence":"first","affiliation":[{"name":"School of Medicine, Tehran University of Medical Sciences","place":["Tehran, Iran"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parsa","family":"Babaei Zadeh","sequence":"additional","affiliation":[{"name":"Faculty of Medicine and Dentistry, University of Alberta","place":["Edmonton, AB, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marko M.","family":"Popovic","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Vision Sciences, University of Toronto","place":["Toronto, ON, Canada"]},{"name":"Department of Ophthalmology, Unity Health Toronto","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Gorin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Human Genetics, University of California, Los Angeles","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Eshkoly-Lior","sequence":"additional","affiliation":[{"name":"Retinal Disorders and Ophthalmic Genetics Division, Stein Eye Institute, University of California, Los Angeles, David Geffen School of Medicine at UCLA","place":["Los Angeles, CA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03253-4","article-title":"Pachychoroid disease: review and update","volume":"39","author":"Cheung","year":"2025","journal-title":"Eye (Lond)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: Recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich","year":"2015","journal-title":"Prog Retin Eye Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/IAE.0000000000000837","article-title":"Risk factors for central serous chorioretinopathy: A systematic review and meta-analysis","volume":"36","author":"Liu","year":"2016","journal-title":"Retina"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s40123-025-01220-0","article-title":"Global incidence of central serous chorioretinopathy: A systematic review, meta-analysis, and forecasting study","volume":"14","author":"Frederiksen","year":"2025","journal-title":"Ophthalmol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.02.032","article-title":"The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980-2002","volume":"115","author":"Kitzmann","year":"2008","journal-title":"Ophthalmology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.14-16360","article-title":"Associations between topical ophthalmic corticosteroids and central serous chorioretinopathy: A Taiwanese population-based study","volume":"56","author":"Chang","year":"2015","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2015.04.002","article-title":"Choroidal mast cells in retinal pathology: a potential target for intervention","volume":"185","author":"Bousquet","year":"2015","journal-title":"Am J Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00335.2005","article-title":"Effect of histamine and cimetidine on retinal and choroidal blood flow in humans","volume":"289","author":"Resch","year":"2005","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1174","article-title":"Intravenous administration of diphenhydramine reduces histamine-induced vasodilator effects in the retina and choroid","volume":"47","author":"Weigert","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s10238-024-01361-9","article-title":"Mast cells in human choroid and their role in age-related macular degeneration (AMD)","volume":"24","author":"Ribatti","year":"2024","journal-title":"Clin Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1186\/s13052-022-01386-4","article-title":"Central serous chorioretinopathy in a 14-year-old atopic boy: a case report","volume":"49","author":"Ranno","year":"2023","journal-title":"Ital J Pediatr"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.3190","article-title":"Role of the complement system in chronic central serous chorioretinopathy: A genome-wide association study","volume":"136","author":"Schellevis","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/b978-1-4557-0737-9.00072-2","article-title":"The association between central serous chorioretinopathy and sleep apnea: A nationwide population-based study","volume":"40","author":"Liu","year":"2020","journal-title":"Retina"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/09286586.2021.1925306","article-title":"Relationship between obstructive sleep apnea and central serous chorioretinopathy: A health insurance database study","volume":"29","author":"Lee","year":"2022","journal-title":"Ophthalmic Epidemiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"100770","DOI":"10.1016\/j.preteyeres.2019.07.003","article-title":"Central serous chorioretinopathy: Towards an evidence-based treatment guideline","volume":"73","author":"van Rijssen","year":"2019","journal-title":"Prog Retin Eye Res"},{"key":"B16","first-page":"67","article-title":"Photodynamic therapy and central serous chorioretinopathy","volume":"1","author":"Siaudvytyte","year":"2012","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-025-03894-z","article-title":"Treatment of central serous chorioretinopathy: new options for an old disease","volume":"39","author":"Kim","year":"2025","journal-title":"Eye (Lond)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001443","article-title":"Acute central serous chorioretinopathy: Factors influencing episode duration","volume":"37","author":"Daruich","year":"2017","journal-title":"Retina"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-023-02509-9","article-title":"Randomized controlled trials in central serous chorioretinopathy: A review","volume":"37","author":"Singh","year":"2023","journal-title":"Eye (Lond)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2021.06.020","article-title":"Half-dose photodynamic therapy versus eplerenone in chronic central serous chorioretinopathy (SPECTRA): A randomized controlled trial","volume":"233","author":"van Rijssen","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2024.101236","article-title":"Central serous chorioretinopathy: An evidence-based treatment guideline","volume":"101","author":"Feenstra","year":"2024","journal-title":"Prog Retin Eye Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/s0140-6736(19)32981-2","article-title":"Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial","volume":"395","author":"Lotery","year":"2020","journal-title":"Lancet"},{"key":"B23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajo.2024.08.040","article-title":"Targeting the Tie-2 receptor with faricimab in central serous chorioretinopathy: A case series motivated by a genetic finding","volume":"269","author":"R\u00e4m\u00f6","year":"2025","journal-title":"Am J Ophthalmol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.09.024","article-title":"Risk factors for central serous chorioretinopathy: a case-control study","volume":"111","author":"Haimovici","year":"2004","journal-title":"Ophthalmology"},{"key":"B25","article-title":"A study on risk factors associated with central serous chorioretinopathy and relation between risk factors and visual recovery","volume":"11","author":"Das","year":"2020","journal-title":"Indian J Public Health Res Dev"},{"key":"B26","article-title":"Management of central serous retinopathy","volume":"31","author":"Murthy","year":"1983","journal-title":"Indian J Ophthalmol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/eye.1997.49","article-title":"The distribution of immune cells in the uveal tract of the normal eye","volume":"11","author":"McMenamin","year":"1997","journal-title":"Eye (Lond)"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051089","article-title":"Advanced glycation endproducts inhibit prostacyclin production and induce plasminogen activator inhibitor-1 in human microvascular endothelial cells","volume":"41","author":"Yamagishi","year":"1998","journal-title":"Diabetologia"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2010.199216","article-title":"C-reactive protein and complement factor H in aged human eyes and eyes with age-related macular degeneration","volume":"95","author":"Bhutto","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2006.05.010","article-title":"Drusen complement components C3a and C5a promote choroidal neovascularization","volume":"103","author":"Nozaki","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v89.8.2863","article-title":"C3a and C5a stimulate chemotaxis of human mast cells","volume":"89","author":"Hartmann","year":"1997","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-023-02628-3","article-title":"The choroidal nervous system: a link between mineralocorticoid receptor and pachychoroid","volume":"146","author":"Leclercq","year":"2023","journal-title":"Acta Neuropathol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2118510119","article-title":"Mast cell infiltration of the choroid and protease release are early events in age-related macular degeneration associated with genetic risk at both chromosomes 1q32 and 10q26","volume":"119","author":"Mcharg","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"B34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1001\/jamaophthalmol.2023.0706","article-title":"Overlap of Genetic Loci for Central Serous Chorioretinopathy With Age-Related Macular Degeneration","volume":"141","author":"R\u00e4m\u00f6","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072034","article-title":"Characteristics of pachychoroid diseases and age-related macular degeneration: Multimodal imaging and genetic backgrounds","volume":"9","author":"Yamashiro","year":"2020","journal-title":"J Clin Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2019.1596800","article-title":"Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders","volume":"15","author":"Theoharides","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1172\/jci115016","article-title":"Recruitment of neutrophils during IgE-dependent cutaneous late phase reactions in the mouse is mast cell-dependent. Partial inhibition of the reaction with antiserum against tumor necrosis factor-alpha","volume":"87","author":"Wershil","year":"1991","journal-title":"J Clin Invest"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0132367","article-title":"Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo","volume":"10","author":"Ashina","year":"2015","journal-title":"PloS One"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00108","article-title":"Histamine regulates molecular clock oscillations in human retinal pigment epithelial cells via H1receptors","volume":"9","author":"Morioka","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajoc.2020.100614","article-title":"Presumed mast cell choroidal infiltrate in aggressive systemic mastocytosis","volume":"18","author":"Tran","year":"2020","journal-title":"Am J Ophthalmol Case Rep"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.03-1235","article-title":"Intravenously administered histamine increases choroidal but not retinal blood flow","volume":"45","author":"Zawinka","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.17-22989","article-title":"Mast cell-derived tryptase in geographic atrophy","volume":"58","author":"McLeod","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph17249455","article-title":"Temporal association between topical ophthalmic corticosteroids and the risk of central serous chorioretinopathy","volume":"17","author":"Chang","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.105298","article-title":"Treatment of central serous chorioretinopathy with topical difluprednate: A literature review","volume":"18","author":"Chatterjee","year":"2026","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","first-page":"14111","DOI":"10.1038\/s41598-023-41126-0","article-title":"Ocular steroidome in human eyes and in eyes with complex central serous chorioretinopathy (CSCR)","volume":"13","author":"Zola","year":"2023","journal-title":"Sci Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1799560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T05:51:03Z","timestamp":1791352263000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1799560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2026.1799560"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1799560","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1799560"}}